Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL26599523 | 1.00 | MET (0.37) | METPDE3BPDE3APIM1KHK | |
| SCHEMBL26669890 | 0.87 | MET (0.41) | METPDE3BPDE3APIM1HTR2C | |
| Trifluoroacetic Acid SCHEMBL30282808 | 0.79 | HRH4 (0.42) | IRAK4PKM | |
| Trifluoroacetic Acid SCHEMBL26599776 | 0.79 | HRH4 (0.42) | IRAK4PKM | |
| Trifluoroacetic Acid SCHEMBL5633122 | 0.79 | PKM (0.40) | HTR2CHTR2AGSK3BRAD52PKM | |
| Trifluoroacetic Acid SCHEMBL5631915 | 0.79 | PKM (0.40) | HTR2CHTR2AGSK3BRAD52PKM | |
| SCHEMBL15823875 | 0.77 | IRAK4 (0.41) | METPDE3BPDE3AHTR2CHTR2A | |
| Trifluoroacetic Acid SCHEMBL5632214 | 0.76 | RAD52 (0.44) | HTR2CHTR2ARAD52 | |
| Trifluoroacetic Acid SCHEMBL21816594 | 0.72 | PKM (0.36) | HTR2CHTR2APKM | |
| Trifluoroacetic Acid SCHEMBL21816711 | 0.72 | PKM (0.36) | HTR2CHTR2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | MET 1419/4885PDE3B 3303/4885PDE3A 4045/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | MET 1419/4885PDE3B 3303/4885PDE3A 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.